Abstract
Alterations of immunological parameters were analysed in patients with advanced malignancies during a phase I trial with rIL-2. Five-day infusions of rIL-2 at doses from 1 x 10(6) to 24 x 10(6) biological response modifiers program (BRMP) U/m2 per day were given to 29 patients, with a minimum of three patients per dose. The dose of 24 x 10(6) U/m2 per day was the maximal tolerated dose (MTD). Immunological parameters were analyzed at days 0, 8 and 11 of the rIL-2 courses. Following a leucopenia during rIL-2 infusion, a lymphocytosis was found in all patients except one. The lymphocytosis peaked at day 8 and was detected at doses of rIL-2 as low as 1 x 10(6) U/m2 per day, reaching a plateau at a dose of 16 x 10(6) U/m2 per day. Although all lymphocyte subsets were increased in patients receiving rIL-2, some patients had predominant T cells (CD3+, NKH1(CD56)-), others had predominant natural killer (NK) cells (CD3-, NKH1 (CD56)+), and yet others showed a mixed profile. A strong induction of cells cytotoxic for K562 targets was found in all patients at days 8 and 11. Eighteen patients received, 1 month later, a second treatment in which infusion of rIL-2 was preceded by a course of 5 days infusion of 2 x 10(6) U/m2 per day recombi...Continue Reading
References
Sep 10, 1976·Science·D A MorganR Gallo
Jan 1, 1989·Cancer Immunology, Immunotherapy : CII·M ToledanoW H Fridman
Nov 1, 1989·European Journal of Cancer & Clinical Oncology·W H Fridman
Feb 1, 1989·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·S P CreekmoreR I Fisher
Oct 1, 1988·Immunology Today·T Hercend, R E Schmidt
Jul 1, 1986·European Journal of Immunology·L K ChenA Bensussan
Jan 15, 1987·Nature·M MalkovskýW Fiers
May 15, 1988·International Journal of Cancer. Journal International Du Cancer·C Gambacorti-PasseriniG Parmiani
Oct 19, 1988·Journal of the National Cancer Institute·J M RichardsN J Vogelzang
Sep 1, 1986·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·M B AtkinsJ W Mier
Apr 9, 1987·The New England Journal of Medicine·S A RosenbergJ T Rubin
Apr 9, 1987·The New England Journal of Medicine·W H WestR K Oldham
Mar 1, 1985·The Journal of Clinical Investigation·T HercendJ Ritz
Jun 1, 1982·The Journal of Experimental Medicine·E A GrimmS A Rosenberg
Mar 16, 1983·Biochemical and Biophysical Research Communications·D A WeigentH M Johnson
Oct 1, 1984·The Journal of Experimental Medicine·R H ZublerH R MacDonald
Citations
Jan 1, 1992·Biotherapy·F FaraceF Triebel
May 1, 1995·British Journal of Urology·N ThiounnB Debre
Jul 9, 1993·International Journal of Cancer. Journal International Du Cancer·F FaraceF Triebel
Jan 1, 1993·Journal of Cancer Research and Clinical Oncology·A SchomburgJ Atzpodien
Aug 1, 1993·Clinical and Experimental Immunology·K YonedaE Ueta
Jan 1, 1994·Biomedicine & Pharmacotherapy = Biomédecine & Pharmacothérapie·E TartourW H Fridman
Jan 1, 1992·Medical Oncology and Tumor Pharmacotherapy·H NaganumaR Kiessling